Form 4 Filing for Joseph Douglas Lyon

Joseph Douglas Lyon, Chief Accounting & Technology Officer at CORCEPT THERAPEUTICS INC, reported a sale of 1540 shares of Common Stock on August 3, 2026, at a price of $114.16 per share. This transaction resulted in a post-transaction ownership of 5495 shares. The filing also includes information about 1783 shares underlying unvested restricted stock awards granted on various dates, with vesting contingent on the Reporting Person meeting certain requirements. The shares underlying these awards will vest one year after the grant date.